Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.43 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.31 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.30 |
| ▸ | KDM5A | P29375 | 1/20 | 0.30 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.30 |
| ▸ | PHF8 | Q9UPP1 | 1/20 | 0.30 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14434683 | 0.95 | — | — | |
| SCHEMBL29012367 | 0.82 | CYP1A2 (0.42) | CYP1A2SIGMAR1CHRM2CHRM4CHRM5 | |
| SCHEMBL13673452 | 0.79 | HRH3 (0.39) | — | |
| SCHEMBL6033221 | 0.75 | CYP1A2 (0.46) | CYP1A2SIGMAR1SLC18A3CHRM5EPHX1 | |
| SCHEMBL8231811 | 0.75 | CYP1A2 (0.52) | CYP1A2SIGMAR1EPHX1GPR84KDM5A | |
| SCHEMBL2076622 | 0.75 | CYP1A2 (0.46) | CYP1A2SIGMAR1EPHX1GPR84KDM5A | |
| SCHEMBL9242305 | 0.75 | CYP1A2 (0.52) | CYP1A2SIGMAR1EPHX1GPR84KDM5A | |
| SCHEMBL7078699 | 0.75 | CYP1A2 (0.46) | CYP1A2SIGMAR1SLC18A3EPHX1 | |
| SCHEMBL5148005 | 0.75 | CYP1A2 (0.58) | CYP1A2SIGMAR1EPHX1 | |
| SCHEMBL21558940 | 0.75 | SIGMAR1 (0.36) | CYP1A2SIGMAR1GPR84 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| EP-1377970-A1 | OPTICAL DATA CARRIER CONTAINING A CYCLIZABLE COMPOUND IN THE INFORMATION LAYER | Bayer Chemicals AG (DE) | 2004-01-07 | — | — | EP | disclosed |
| US-20020197561-A1 | Optical data carrier comprising a cyclizable compound in the information layer | LANXESS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002080163-A1 | OPTICAL DATA CARRIER CONTAINING A CYCLIZABLE COMPOUND IN THE INFORMATION LAYER | BAYER AKTIENGESELLSCHAFT (DE) | 2002-10-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | CYP1A2 1299/4885SIGMAR1 3848/4885SLC18A3 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.